Xlife Sciences AG (XSWX:XLS) Owner Earnings per Share (TTM): 2.71 (As of Dec. 2025) — 67% Below Median


XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF18.15
GF Value CHF7.26
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Owner Earnings per Share (TTM)?

Xlife Sciences AG XSWX:XLS +0.83% 53 Owner Earnings per Share (TTM) is 2.71 as of Dec. 2025, which is 67% below its 10-year median of 8.23. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.26 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 206 Biotechnology companies, Xlife Sciences AG ranks better than 81.55% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Xlife Sciences AG's Owner Earnings per Share (TTM) ended in Dec. 2025 was CHF2.71. It's Price-to-Owner-Earnings ratio for today is 6.7.


The historical rank and industry rank for Xlife Sciences AG's Owner Earnings per Share (TTM) or its related term are showing as below:

XSWX:XLS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.69   Med: 8.23   Max: 13.96
Current: 7.46


During the past 8 years, the highest Price-to-Owner-Earnings ratio of Xlife Sciences AG was 13.96. The lowest was 2.69. And the median was 8.23.


XSWX:XLS's Price-to-Owner-Earnings is ranked better than
81.55% of 206 companies
in the Biotechnology industry
Industry Median: 25.615 vs XSWX:XLS: 7.46

Xlife Sciences AG's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was CHF-3.23. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.76. It's PE Ratio (TTM) ratio for today is At Loss.

Xlife Sciences AG's EPS without NRI for the six months ended in Dec. 2025 was CHF-3.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.74. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Xlife Sciences AG Owner Earnings per Share (TTM) Related Terms


Xlife Sciences AG Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Owner Earnings per Share (TTM) Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial 0.00 3.99 3.60 6.44 2.71

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.60 0.00 6.44 0.00 2.71

XSWX:XLS vs VRTX, REGN, ALNY: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, Xlife Sciences AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xlife Sciences AG Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Price-to-Owner-Earnings falls into.


XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Xlife Sciences AG's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income -21.55
Depreciation, Depletion and Amortization 28.36
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.28
Change In Working Capital 13.35
Shares Outstanding (Diluted Average) 7.34

1. Start with "Net Income" from income statement. Xlife Sciences AG's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-21.55 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Xlife Sciences AG's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2025 was CHF28.36 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Xlife Sciences AG's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = CHF0.28 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Xlife Sciences AG's 5-Year Average Maintenance Capital Expenditure = CHF0.28 Mil

5. "Change In Working Capital" is from cashflow statement. Xlife Sciences AG's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 was CHF13.35 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Xlife Sciences AG's Shares Outstanding (Diluted Average) for the months ended in Dec. 2025 was 7.342 Mil.

Xlife Sciences AG's Onwer Earnings Per Share for Dec. 2025 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -21.547 +28.358+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.2754+13.345)/7.342
=2.71

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=18.15/2.71
=6.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 2.71 mean?
Xlife Sciences AG (XSWX:XLS) has a Owner Earnings per Share (TTM) of 2.71 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Xlife Sciences AG. This is 67% below median its historical median of 8.23. Over the past decade, Xlife Sciences AG's Owner Earnings per Share (TTM) has ranged from 2.69 to 13.96. According to the industry distribution chart, Xlife Sciences AG ranks #38 out of 206 companies in the Biotechnology industry, placing it in the top 18.4%.
Is Xlife Sciences AG's Owner Earnings per Share (TTM) too high?
Xlife Sciences AG's current Owner Earnings per Share (TTM) of 2.71 is 67% below median its 10-year median of 8.23. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 13.96. The Biotechnology industry median Owner Earnings per Share (TTM) is 25.62. Xlife Sciences AG's value of 2.71 is 89.4% below this industry median. Based on the distribution chart, Xlife Sciences AG ranks #38 out of 206 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Owner Earnings per Share (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #38 out of 206 companies for Owner Earnings per Share (TTM). This places Xlife Sciences AG in the top 18% of its industry — outperforming the majority of peers. The industry median Owner Earnings per Share (TTM) is 25.62. Xlife Sciences AG's value of 2.71 is 89.4% below this benchmark. Historically, Xlife Sciences AG's own Owner Earnings per Share (TTM) has ranged from 2.69 to 13.96 over the past decade. While the company's 10-year median is 8.23 vs. the industry median of 25.62, Xlife Sciences AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 25.62, based on 206 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Owner Earnings per Share (TTM) of 2.71 is 89.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Xlife Sciences AG. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 25.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Owner Earnings per Share (TTM) is 2.71, which is 67% below median its own 10-year median of 8.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.26, compared to a current price of CHF18.15 — trading 150% above its estimated fair value. The current Owner Earnings per Share (TTM) is 2.71, which is 67% below median its 10-year median of 8.23 and 89.4% below the Biotechnology industry median of 25.62. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Owner Earnings per Share (TTM) is 2.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF18.15 is trading 150% above its estimated GF Value™ of CHF7.26. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Owner Earnings per Share (TTM): 2.71 (67% below median its 10-year median of 8.23)
  • GF Value™: CHF7.26 vs. price of CHF18.15 (150% above fair value)
  • GF Score™: 53/100 with 10 warning signs
  • Industry Position: 89.4% below the Biotechnology median (#38 of 206)

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.15
Price
CHF7.26
GF Value